Image-Guided Adaptive Conformal Photon Versus Proton Therapy
Phase: Phase 2
Diagnosis: Lung Cancer
NCT ID: NCT00915005
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 09-247
The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in the irradiated area after treatment) in patients with lung cancer. Primary Objective: - Assess and compare the incidence and time to development of CTCAE v3.0 grade > 3 treatment related pneumonitis (TRP) or locoregional recurrence, whichever comes first, among patients with locally advanced (stage II-IIIb and selected stage IV) non-small cell lung cancer (NSCLC) treated with image-guided adaptive photon therapy (IGAXT, group 1) or proton therapy (IGAPT, group 2) using Bayesian randomization. Secondary Objectives: - Assess and compare the incidence and time to development of CTCAE v3.0 grade > 3 radiation esophagitis in treatment groups 1 and 2. - Investigate the association of inflammatory cytokines with the incidence and time to development of TRP and outcomes in treatment groups 1 and 2. - Investigate the association of relevant pharmacogenetic markers, biomarkers, and gene polymorphisms with the time to development of TRP and treatment outcomes in treatment groups 1 and 2. - Evaluate IGAXT using weekly computed tomography (CT) on-rail or cone beam CT in the assessment of tumor response and impact on treatment planning and delivery. - Compare overall survival, progression-free survival, and median survival time in treatment groups 1 and 2. - Evaluate the role of functional imaging with FDG-PET in assessing and predicting the time to the development of TRP and tumor response. - Document and compare symptom burden weekly during treatment, monthly up to 6 month after the treatment, and at each follow-up visit by using the M. D. Anderson Symptom Inventory for Lung (MDASI-Lung) in treatment groups 1 and 2.
Massachusetts General Hospital
Noah Choi, MD,
Massachusetts General Hospital
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
1. Pathologically proven, unresected, locoregionally advanced NSCLC without evidence of
hematogenous metastases (stage II-IIIB disease according to the 6th edition of the
AJCC Staging Manual) with exception as defined by inclusion #2).
2. Patients with solitary brain metastasis without sign of progression in the brain at
the time of registration will be eligible for this trial if there is clinical
indication for concurrent chemoradiation to the primary disease in the lung.
3. Suitability for concurrent chemoradiation therapy per treating radiation oncologists
or treating medical oncologist's: A) Karnofsky performance score of >/= 70, or ECOG
0-1 B) Unintentional weight loss </= 10% during the 3 months before study entry.
4. Receipt of induction chemotherapy followed by referral for concurrent chemoradiation.
5. Measurable disease on chest x-ray, contrast-enhanced CT, or PET scan.
6. Locoregional recurrence after surgical resection, if suitable for definitive
7. Forced expiratory volume in the first second (FEV1) >/= 1 liters.
8. Fluorodeoxyglucose (FDG) -PET scan within 3 months before registration. The
pretreatment (diagnostic) PET/CT should be performed together with the 4-D CT
simulation. If PET/CT is not available, PET image acquired separately may be fused
with the 4D CT.
9. Standard pretreatment evaluations (as decided by treating radiation oncologists,
medical oncologist, surgeons or pulmonologists), to include MRI or CT scan of the
brain, contrast CT scan of the thorax and upper abdomen, pulmonary function tests,
lung and cardiac single proton emission computed tomography (SPECT), liver function
tests (LFT), blood chemistry, renal function tests, and complete blood count.
10. Age >/= 18 years but </= 85 years.
11. A signed specific informed consent form before study entry.
1. Small cell histology.
2. Prior radiotherapy to regions that would result in overlap of radiation therapy
3. Pregnancy (female patients of childbearing potential must practice appropriate
4. Enrollment in a clinical trial that specifically excludes IGAPT treatment.
5. Patients with implanted device(s) that prohibit patients from having proton treatment
(cardiac pace maker, defibrillator, neurotransmitter, etc).
6. Previous or concomitant malignancy other than (a) curatively treated carcinoma in
situ of cervix, (b) basal cell carcinoma of the skin, (c) curatively treated
superficial transitional cell carcinoma of the urinary bladder, and (d) early stage
tumor treated more than 3 years ago for cure.